{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:59:15Z","timestamp":1760425155801},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-244x-12-218","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T11:56:57Z","timestamp":1354622217000},"source":"Crossref","is-referenced-by-count":10,"title":["Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study"],"prefix":"10.1186","volume":"12","author":[{"given":"Jihyung","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Novick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Brugnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Karagianis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dossenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,4]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00023210-200418030-00002","volume":"18","author":"Z Zhao","year":"2004","unstructured":"Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B, Breier A: Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS Drugs. 2004, 18: 157-164. 10.2165\/00023210-200418030-00002.","journal-title":"CNS Drugs"},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pds.703","volume":"11","author":"DM Ashcroft","year":"2002","unstructured":"Ashcroft DM, Frischer M, Lockett J, Chapman SR: Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf. 2002, 11: 285-289. 10.1002\/pds.703.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1176\/appi.ps.53.4.425","volume":"53","author":"RC Hermann","year":"2002","unstructured":"Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M: Prescription of antipsychotic drugs by office-based physicians in the United States, 1989\u20131997. Psychiatr Serv. 2002, 53: 425-430. 10.1176\/appi.ps.53.4.425.","journal-title":"Psychiatr Serv"},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4088\/JCP.v67n1013","volume":"67","author":"H Takahashi","year":"2006","unstructured":"Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H: Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J Clin Psychiatry. 2006, 67: 1577-1582. 10.4088\/JCP.v67n1013.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"1131_CR5","first-page":"28","volume":"62","author":"MR Dossenbach","year":"2001","unstructured":"Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH: Evidence for the effectiveness of olanzapine among patients nonresponsive and\/or intolerant to risperidone. J Clin Psychiatry. 2001, 62 (Suppl 2): 28-34.","journal-title":"J Clin Psychiatry"},{"key":"1131_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1185\/030079908X297385","volume":"24","author":"DE Faries","year":"2008","unstructured":"Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin. 2008, 24: 1399-1405. 10.1185\/030079908X297385.","journal-title":"Curr Med Res Opin"},{"key":"1131_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1034\/j.1600-0447.2003.00064.x","volume":"107","author":"JM Haro","year":"2003","unstructured":"Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M: The european schizophrenia outpatient health outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003, 107: 222-232. 10.1034\/j.1600-0447.2003.00064.x.","journal-title":"Acta Psychiatr Scand"},{"key":"1131_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1600-0447.2004.00450.x","volume":"111","author":"JM Haro","year":"2005","unstructured":"Haro JM, Edgell ET, Novick D, et al: Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand. 2005, 111: 220-231. 10.1111\/j.1600-0447.2004.00450.x.","journal-title":"Acta Psychiatr Scand"},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4088\/JCP.v66n0810","volume":"66","author":"M Dossenbach","year":"2005","unstructured":"Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S: Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005, 66: 1021-1030. 10.4088\/JCP.v66n0810.","journal-title":"J Clin Psychiatry"},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/j.1742-1241.2009.02191.x","volume":"63","author":"J Karagianis","year":"2009","unstructured":"Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ: Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009, 63: 1578-1588. 10.1111\/j.1742-1241.2009.02191.x.","journal-title":"Int J Clin Pract"},{"key":"1131_CR11","volume-title":"Diagnostic and statistical manual of mental disorders","author":"APA","year":"1994","unstructured":"APA: Diagnostic and statistical manual of mental disorders. 1994, Washington, DC: American Psychiatric Association (APA), Fourth","edition":"Fourth"},{"key":"1131_CR12","volume-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"WHO","year":"1992","unstructured":"WHO: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992, Geneva, Switzerland: World Health Organisation (WHO)"},{"key":"1131_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","volume":"416","author":"JM Haro","year":"2003","unstructured":"Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, et al: The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003, 416: 16-23.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"1131_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/01.jcp.0000246215.49271.b8","volume":"26","author":"JM Haro","year":"2006","unstructured":"Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M: Remission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2006, 26: 571-578. 10.1097\/01.jcp.0000246215.49271.b8.","journal-title":"J Clin Psychopharmacol"},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1741-7015-6-17","volume":"6","author":"R Ganguli","year":"2008","unstructured":"Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ: Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med. 2008, 6: 17-10.1186\/1741-7015-6-17.","journal-title":"BMC Med"},{"key":"1131_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006, 163: 611-622. 10.1176\/appi.ajp.163.4.611.","journal-title":"Am J Psychiatry"},{"key":"1131_CR17","volume-title":"Risperidone versus olanzapine for schizophrenia. Cochrane database of systematic reviews cochrane database of systematic reviews","author":"MB Jayaram","year":"2006","unstructured":"Jayaram MB, Hosalli P, Stroup TS: Risperidone versus olanzapine for schizophrenia. Cochrane database of systematic reviews cochrane database of systematic reviews. 2006, Issue 2:Art. No.: CD005237"},{"key":"1131_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","volume":"17","author":"PV Tran","year":"1997","unstructured":"Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997, 17: 407-418. 10.1097\/00004714-199710000-00010.","journal-title":"J Clin Psychopharmacol"},{"key":"1131_CR19","doi-asserted-by":"publisher","first-page":"S315","DOI":"10.1016\/S0924-977X(02)80471-0","volume":"12","author":"M Namjoshi","year":"2002","unstructured":"Namjoshi M, Young C, Huang L, et al: Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial. Eur Neuropsychopharmacol. 2002, 12: S315-","journal-title":"Eur Neuropsychopharmacol"},{"key":"1131_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1192\/bjp.187.2.137","volume":"187","author":"S Park","year":"2005","unstructured":"Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB: Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry. 2005, 187: 137-142. 10.1192\/bjp.187.2.137.","journal-title":"Br J Psychiatry"},{"key":"1131_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1192\/bjp.171.6.509","volume":"171","author":"M Knapp","year":"1997","unstructured":"Knapp M: Costs of schizophrenia. Br J Psychiatry. 1997, 171: 509-518. 10.1192\/bjp.171.6.509.","journal-title":"Br J Psychiatry"},{"key":"1131_CR22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2165\/00019053-200018020-00002","volume":"18","author":"E Lindstrom","year":"2000","unstructured":"Lindstrom E, Bingefors K: Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics. 2000, 18: 106-124.","journal-title":"Pharmacoeconomics"},{"key":"1131_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","volume":"35","author":"S Leucht","year":"1999","unstructured":"Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999, 35: 51-68. 10.1016\/S0920-9964(98)00105-4.","journal-title":"Schizophr Res"},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/13543784.8.4.443","volume":"8","author":"NA Keks","year":"1999","unstructured":"Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999, 8: 443-452. 10.1517\/13543784.8.4.443.","journal-title":"Expert Opin Investig Drugs"},{"key":"1131_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004, 161: 1-56. 10.1176\/appi.ajp.161.1.1.","journal-title":"Am J Psychiatry"},{"key":"1131_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","volume":"17","author":"JM Haro","year":"2007","unstructured":"Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D: Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007, 17: 235-244. 10.1016\/j.euroneuro.2006.09.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1131_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/713847170","volume":"29","author":"J Bobes","year":"2003","unstructured":"Bobes J, Garc APMP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A: Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003, 29: 125-147. 10.1080\/713847170.","journal-title":"J Sex Marital Ther"},{"key":"1131_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1600-0447.2004.00451.x","volume":"111","author":"M Lambert","year":"2005","unstructured":"Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, Naber D: Olanzapine vs. Other antipsychotics in actual out-patient settings: six months tolerability results from the European schizophrenia Out-patient health outcomes study. Acta Psychiatr Scand. 2005, 111: 232-243. 10.1111\/j.1600-0447.2004.00451.x.","journal-title":"Acta Psychiatr Scand"},{"key":"1131_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00023210-200519010-00003","volume":"19","author":"M Edlinger","year":"2005","unstructured":"Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, Hummer M, Fleischhacker WW: Switching between second-generation antipsychotics: why and how?. CNS Drugs. 2005, 19: 27-42. 10.2165\/00023210-200519010-00003.","journal-title":"CNS Drugs"},{"key":"1131_CR30","unstructured":"Highlights of prescribing information for zyprexa. http:\/\/www.zyprexa.com\/Hcp\/Pages\/physiciansandhealthcareprofessionalshome.aspx ,"},{"issue":"Suppl 6","key":"1131_CR31","first-page":"14","volume":"68","author":"PJ Weiden","year":"2007","unstructured":"Weiden PJ, Buckley PF: Reducing the burden of side effects during long-term antipsychotic therapy: the role of \"switching\" medications. J Clin Psychiatry. 2007, 68 (Suppl 6): 14-23.","journal-title":"J Clin Psychiatry"},{"key":"1131_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"1131_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.pnpbp.2006.03.041","volume":"30","author":"H Takahashi","year":"2006","unstructured":"Takahashi H, Yoshida K, Ishigooka J, Higuchi H: Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30: 1067-1072. 10.1016\/j.pnpbp.2006.03.041.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1131_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.psyneuen.2009.01.013","volume":"34","author":"M van Bruggen","year":"2009","unstructured":"van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D: Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology. 2009, 34: 989-995. 10.1016\/j.psyneuen.2009.01.013.","journal-title":"Psychoneuroendocrinology"},{"key":"1131_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00148365-200605010-00003","volume":"5","author":"JM Haro","year":"2006","unstructured":"Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F: Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy. 2006, 5: 11-25. 10.2165\/00148365-200605010-00003.","journal-title":"Appl Health Econ Health Policy"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-12-218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-12-218\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-12-218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T11:31:10Z","timestamp":1562412670000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-12-218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-12-218","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"article-number":"218"}}